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Abstract
Background: Neoplastic transformation is a multistep process in which distinct gene products of
specific cell regulatory pathways are involved at each stage. Identification of overexpressed genes
provides an unprecedented opportunity to address the immune system against antigens typical of
defined stages of neoplastic transformation. HER-2/neu/ERBB2 (Her2) oncogene is a prototype of
deregulated oncogenic protein kinase membrane receptors. Mice transgenic for rat Her2 (BALB-
neuT mice) were studied to evaluate the stage in which vaccines can prevent the onset of Her2
driven mammary carcinomas. As Her2 is not overexpressed in all mammary carcinomas, definition
of an additional set of tumor associated antigens (TAAs) expressed at defined stages by most breast
carcinomas would allow a broader coverage of vaccination. To address this question, a meta-
analysis was performed on two transcription profile studies [1,2] to identify a set of new TAA
targets to be used instead of or in conjunction with Her2.
Results: The five TAAs identified (Tes, Rcn2, Rnf4, Cradd, Galnt3) are those whose expression is
linearly related to the tumor mass increase in BALB-neuT mammary glands. Moreover, they have
a low expression in normal tissues and are generally expressed in human breast tumors, though at
a lower level than Her2.
Conclusion: Although the number of putative TAAs identified is limited, this pilot study suggests
that meta-analysis of expression profiles produces results that could assist in the designing of pre-
clinical immunopreventive vaccines.
Background
One of the most significant tenet of tumor immunology is
the assumption that the immune system is able to dis-
criminate between normal and neoplastic tissues. As this
distinction is based on the overexpression of TAAs, the
discovery of TAAs and their molecular and genetic charac-
terization is important in both tumor immunodiagnosis
and immunotherapy.
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The progressive elucidation of the nature of TAAs recog-
nized by antibodies and T lymphocytes coupled with the
elaboration of methods for their isolation and synthesis
of their peptides is leading towards new formulations of
antitumor vaccines. Despite of the fact that long lists of
well-characterized TAAs recognized by T cells [3] and by
antibodies [4] are currently available, the attempts to use
them to arouse an immune response able to cure tumor
patients has met with very little success, at least so far [5].
Towards this goal significant obstacles are posed by the
patient's state of immunosuppression and the numerous
mechanisms to evade the immune response that a tumor
progressively acquires [6]. This two order of obstacles
might suggest that active immunotherapy is not very
appropriate for patients with advanced tumors.
A more modern endeavor is to exploit the potential of the
immune response elicited by a vaccine against more plau-
sible targets, such as pre-neoplastic lesions. In this case,
the immune response may be addressed towards TAAs
that are already present in early lesions and that remain
overexpressed during the progression of the tumor [7].
Identification of TAAs on preneoplastic cells will provide
the opportunity to trigger the immune system against
transformed cells at their earliest manifestation [8]. The
availability of animal models of autochthonous carcino-
genesis offers an unprecedented opportunity to identify
this kind of TAAs and to test the efficacy of the immune
control of preneoplastic lesions [9]. A preneoplastic lesion
formed by few cells characterized by an indolent prolifer-
ation both displays a limited genetic instability and is
more permeable to an immune attack than a large tumor
[10,11]. In addition it is possible that early expressed
TAAs are more suitable target for tumor immune preven-
tion than most of the already defined TAAs.
The characterization of TAAs expressed in early lesions is
a prerequisite for setting up protocols for tumor preven-
tion instead of for tumor cure [12]. The protein product of
the oncogene Her2 [13], IGF-R [14] and cyclin B1 [15] are
significant examples of early expressed TAAs causally
involved in the progression of the lesions [7].
Mouse strains transgenic for oncogenes or knock-out for
oncosuppressor genes that consequently develop defined
kind of tumors are being used for preclinical assessment
of the potential of preventive vaccines [16,11].
By combining the information provided by the genome
sequence and the expression profiles of entire transcrip-
tomes (microarrays), these mouse models can also lead
towards the identification of TAAs expressed during pro-
gressive stages of carcinogenesis. Microarrays are an attrac-
tive way of identifying new TAAs since their procedure is
now firmly established [17] and they are well suited to the
intrinsic limitations of the biological material to be exam-
ined (e.g. the small amount of starting material). This
paper describes our application of meta-analysis to two
BALB-neuT mice transcription profiling studies [1,2] to
evaluate the possibility of identifying, within the tumor
modulated genes, a set of new putative targets to be used
as TAAs instead of or in conjunction with Her2.
Results and discussion
Our previous demonstration of persistent inhibition of
autochthonous preneoplastic lesions in a mouse model of
Her2 mammary carcinogenesis by a combined DNA and
cell vaccine [1], and the curing of Her2 transplantable
tumors by DNA vaccination [18] indicates that efficient
immunological inhibition of Her2 carcinogenesis can be
achieved. We have also shown that two transcriptional
profiling studies based on different immunization proto-
cols in BALB-neuT mice [1,2] are integrable [17]. Since an
important issue of DNA vaccination is the definition of a
set of target genes other that Her2 in order to broaden its
effective coverage, we decided to use these data to identify
a set of new TAAs to be used in DNA vaccination.
Datasets
Seven prototypic situations were evaluated. Mammary
glands from: (a) 6-week-old mice (wk6nt), displaying
atypical hyperplasia; (b) 10-week-old mice (wk10nt),
showing atypical hyperplasia and some foci of in situ car-
cinomas; (c) 15-week-old mice (wk15nt), with diffuse
hyperplasia and in situ carcinomas; (d) 19-week-old mice
(wk19nt), displaying lobular invasive carcinomas; (e) 22-
week-old mice (wk22nt), with palpable carcinomas; (f)
26-week-old mice (wk26nt), with large lobular and
metastasizing carcinomas, (g) 2-week-pregnant (wk2prg)
wild type BALB/c mice displaying marked pregnancy-
related hyperplasia [19,1]. wk6nt, wk15nt, wk19nt and
wk26nt gland expression profiles were derived from Asto-
lfi [2], wk10nt, wk22nt and wk2prg gland profiles from
Quaglino [1].
Selection of genes whose expression is linearly correlated 
with the increase of the tumor
The number of neoplastic cells in the mammary tissue of
BALB-neuT mice increases constantly during aging, and at
19–22 weeks a tumor mass becomes palpable in all their
mammary glands. Previously [17] we have used PCA
(Principal Component Analysis) to show that the tran-
scriptional profiles of BALB-neuT mammary glands are
linearly correlated with age (i.e. in function of the incre-
ment of tumor cellularity in the mammary glands, fig. 1).
We identified 205 probe sets by linear fitting each gene
expression with respect to age (fig. 2). Only one probe set
was linked to an unmapped EST http://www.bioinformat
ica.unito.it/bioinformatics/Forni3/, whereas the others
were linked to annotated mouse genes. Investigation ofBMC Bioinformatics 2005, 6:S7
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specific gene ontology (GO) class (BP, biological process;
MF, molecular function; CC, cellular component) over-
representation within the annotated 204 genes revealed
significant enrichments in functions associated with the
extracellular compartment (table 1). Pathway analysis
showed the presence of 6 genes involved in the integrin
signal transduction pathway (fig. 3) linked to Her2 action
[20,21].
Evaluation of the expression of tumor-related genes in 
normal mouse tissues
If a TAA is to be used as a vaccination target, its expression
must be low in normal tissues. To evaluate the expression
of the 204 putative TAAs in normal tissues, we used tran-
scription profiles recently published by Su [22]. The
mouse atlas (GNFm) was generated by using a custom
Affymetrix array which interrogates 17,108 annotated
mouse genes: 171 of the putative TAAs are present in
BALB-neuT mammary gland morphology and transcription profiles similarities Figure 1
BALB-neuT mammary gland morphology and transcription profile similarities. A) Morphological preparation 
called "whole mount", that allows the observation of the entire mammary gland. The draining lymph node, vessels, ducts and 
ductules are evident. Clearly the amount of tumor mass increases from 6 to 22 weeks. 19 weeks picture was omitted since it 
is very similar to 22 weeks. At 26 weeks the tumor mass is palpable in all the mammary glands, and the "whole mount" picture 
is very similar to 22 weeks old mice (not shown). B) Euclidean distance of the expression profiles derived by mammary glands 
from 6 to 26 weeks old BALB-neuT mice measured with respect to 6 weeks old mice. Black dots refer to the average distance 
generated using all microarray data. Red dots refer to the average distance calculated using only microarray data showing an 
IQR greater than 0.5.BMC Bioinformatics 2005, 6:S7
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Transcription profiles as virtual two dye experiments Figure 2
Transcription profiles as virtual two dye experiments. Each of the experimental points are represented as ratio with 
respect to wk2prg mice displaying marked pregnancy-related hyperplasia. The expression level of the genes associated to 
tumor cells increases with the animal age since tumor cells are replacing the conventional cellular environment of a normal 
mammary gland.BMC Bioinformatics 2005, 6:S7
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GNFm, twelve of them (table 2) characterized by low
expression (see material and methods) in normal mouse
tissues.
Expression of tumor related genes in normal and cancer 
human tissues
The 12 genes identified as TAAs were expressed in all the
stages of breast carcinogenesis in BALB-neuT mice and
characterized by low expression in normal mouse tissues.
To determine whether these characteristics were also
present in the corresponding human genes, we cross-vali-
dated the expression of the 12 TAAs within the human tis-
sue expression atlas published by Yanai [23]. Since Her2
is expressed at very low levels in normal human tissues,
we used it as the "ideal reference" of low expression. Rtn1,
Irf6, Sel1L were discarded since their expression levels in
some human tissues were higher than those of Her2 (data
not shown). Tes, Rcn2, Rnf4, Cradd, Galnt3, Clca1,
Cdcp1, Socs2 and Spred2 were expressed at levels similar
to Her2.
We also assessed the expression of these 9 TAAs in human
breast specimens. Of the breast cancer transcriptional pro-
filing data sets available [24-26], that proposed by van't
Veer [26] is ideal because its experimental structure allows
evaluation of the expression level distribution within the
specimens. Fold change variation of each specimen is
measured with respect to a reference pool composed by
mixing the same amount of all RNA of the sporadic
patients [26].
The 9 TAAs and Her2 were represented in the van't Veer set
[26], Her2 was highly expressed, while Tes, Rcn2, Rnf4,
Cradd and Galnt3 were medium expressed. Clca1, Cdcp1,
Socs2 and Spred2 were low expressed group (fig. 4) and
since their expression was 100 times lower than that of
Her2 they were discarded as putative vaccination targets.
Even though Tes, Rcn2, Rnf4, Cradd and Galnt3 were less
expressed than Her2, they were less scattered than Her2
(fig. 4). The highest expressed is Tes, which maps to a frag-
ile site on chromosome 7q31.2 [27] and may have a
tumor suppression activity [28]. It is homogeneously
expressed in all the 78 cancer specimens in the van't Veer
set [26]. The function of Rcn2, reticulocalbin, has not
been characterized. It is implicated in tumor cell invasive-
ness, as it is expressed in the highly invasive breast cancer
cell lines, but not in poorly invasive ones [29]. Rnf4 is a
RING-finger protein which acts as a transcription regula-
tor [30], it is not only a coactivator in steroid receptor-
dependent transcription but also activates transcription
from steroid-independent promoters [31]. It is expressed
at very high levels in testis and at much lower levels in sev-
eral other tissues. When ectopically expressed, it inhibits
the proliferation of both somatic and germ cell tumor-
derived cells [32,33]. Cradd encodes a death domain
(CARD/DD)-containing protein and induces apoptosis
[34,35]. Galnt3 encodes UDP-GalNAc transferase 3, a
member of the GalNAc-transferases family. In gallbladder
cancer, the presence of diffuse-type localization of Gal-
NAc-T3 in the subserosal layer is correlated with aggres-
siveness [36]. Furthermore, Galnt3 expression is
associated with the differentiation and aggressiveness of
ductal adenocarcinoma of the pancreas [37].
Conclusion
This study identified 12 putative TAAs. Three were dis-
carded because they were expressed in some normal
human tissues and four because their expression was too
low in human cancer specimens. Tes, Rcn2, Rnf4, Cradd
and Galnt3 were retained for further studies. This work
was based on in silico analysis of published transcrip-
tional profiling studies. Its results must now be referred
back to the in vivo pre-clinical experimentation.
We shall select the most immunogenic domains of the 5
candidate TAAs and use them in vaccination protocols in
BALB-neuT mice [9,38]. Other interesting TAAs may have
been missed in this analysis since it integrates two inde-
pendent experiments and this increases the experimental
noise. A further limitation could be the partial coverage of
the mouse transcriptome of the arrays employed. A new
transcription profiling study covering the same experi-
mental points, but using full genome-wide mouse arrays
is now in progress.
Methods
Microarray data
The .CEL files from Quaglino [1], Astolfi [2], Su [22] were
kindly provided by the authors. The van't Veer data set
[26] was obtained from the Rosetta Inpharmatics web site
http://www.rii.com/publications/2002/default.html.
Data analysis
Microarray data analysis was performed using Bioconduc-
tor libraries [39]. Probe set intensities were calculated
using the gcRMA algorithm http://www.bepress.com/cgi/
viewcontent.cgi?article=1001&context=jhubiostat and
normalized by the quantiles method [40]. The full data set
(wk6nt 4 arrays, wk10nt 2 arrays, wk15t 3 arrays, wk19nt
2 arrays, wk22nt 3 arrays, wk26nt 3 arrays) was filtered to
select probe sets with an intra-experiment Inter Quantile
Range (IQR) greater than 0.5. We used a statistical linear
model to measure the effects of time on gene expression
and to identify probe sets linearly correlated to the incre-
ment of the tumor mass. In equation (1) yij is the observed
expression level for probe set i in sample j (j = 1,...,16). µ
is the average expression level of probe set i and βtime rep-
resents the effect of time on the expression level of probe
set i, ε represents random error for probe set i and sample
j, and is assumed to be independent for each probe set andBMC Bioinformatics 2005, 6:S7
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Table 1: GO classes found enriched by mean of hypergeometric distribution within the 204 genes linearly linked to tumor mass 
increase.
GO class Description p value N. of found items 
within the 204 
differentially 
expressed genes
N. of items 
belonging to the 
GO class within the 
mgu74av2 chip.
GO
GO:0007155 Cell adhesion 0.000 19 250 BP
GO:0030198 Extracellular matrix 
organization and 
biogenesis
0.005 3 17 BP
GO:0007160 Cell-matrix adhesion 0.005 4 34 BP
GO:0005201 Extracellular matrix 
structural constituent
0.003 5 47 MF
GO:0008201 Heparin binding 0.004 4 39 MF
GO:0005576 Extracellular 0.000 58 1631 CC
GO:0005615 Extracellular space 0.000 54 1514 CC
GO:0005794 Golgi apparatus 0.004 12 209 CC
GO:0005581 collagen 0.004 4 28 CC
GO:0016327 Apicolateral plasma 
membrane
0.004 6 65 CC
GO:0016020 Membrane 0.005 69 22285 CC
GO:0030054 Cell junction 0.006 6 71 CC
GO:0005923 Tight junction 0.007 3 17 CC
GO:0005911 Intercellular junction 0.007 5 52 CC
GO:0030057 Desmosome 0.008 2 6 CC
GO:0005578 Extracellular matrix 0.008 11 204 CC
Integrin signal transduction pathway Figure 3
Integrin signal transduction pathway. Part of the integrin signal transduction pathway characterized by an over-represen-
tation of 6/204 genes showing an expression linearly linked to the tumor mass increment. The 6 genes found overrepresented 
are colored in yellow in the integrin pathway.BMC Bioinformatics 2005, 6:S7
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sample, and normally distributed with mean 0 and vari-
ance σ2.
yij = µi + βtime + εij   (1)
205 probe sets were identified as putative TAAs by select-
ing only the expression profiles characterized by an r2 >
0.7, and a positive slope (p < 0.001) of the linear fitting of
expression versus the animal age.
Virtual two-dye experiments were done as previously pub-
lished [1] using as reference wk2prg (3 arrays).
GO class enrichment was evaluated with the Bioconduc-
tor GOstats package and the annotation library mgu74av2
1.6.8. Pathway analysis was performed with the PAN-
THER annotation tool https://panther.appliedbiosys
tems.com/.
Expression level of the probe sets within mouse tissues
was evaluated using the mouse tissue expression atlas
(GNFm) published by Su [22]. 171 of the 204 putative
TAAs were mapped within GNFm. The expression of 12 of
them was located in the low expression tail of the GNFm
distribution (|log2(average intensity)|<7) and narrowly
distributed within the GNFm tissues (IQR of the inter-tis-
sue expression < 0.5). The expression of 12 TAAs was com-
pared to that of Her2 in the human normal tissue
expression atlas published by Yanai [23] by using their
web interface http://genecards.weizmann.ac.il/cgi-bin/
genenote/home_page.pl.
The expression of 9 TAAs was evaluated within the breast
cancer transcription profiling study produced by van't
Veer [26]. Since in this experiment the gene identifiers are
EST accession numbers, the Entrez Gene identifier [41]
associated with each putative TAA was searched in the
Fold change variation versus average intensities of putative  TAAs in van't Veer data set Figure 4
Fold change variation versus average intensities of 
putative TAAs in van't Veer data set. Log10 fold change 
variation with respect to a reference pool (the reference 
pool is made of the same amount of all sporadic patients 
[26]) is plotted in function of log10 average intensities [42]. 
The 9 putative TAAs are grouped with respect to Her2 
expression as medium expressed and low expressed. Genes 
belonging to the medium expressed group have a median 
average expression level between 1/10 to 1/100 of median 
Her2 expression. Genes belonging to the low expressed 
group have a median average expression level lower than 1/
100 of median Her2 expression.
Table 2: Genes, having expression linked to tumor mass increase, showing low expression levels in the GNFm tissue atlas. 12 genes 
were showing a limited expression at transcriptional level in the normal murine tissue expression atlas.
Symbol GNFm ID Mm Affy IDs Mm Gene IDs Hs Gene IDs Expression similar 
to Her2 in human 
tissues
Socs2 gnf1m24576_at 99475_at 216233 8835 Y
Spred2 gnf1m09332_s_at 161070_at 114716 200734 Y
Cdcp1 gnf1m12020_a_at 104198_at 109332 64866 Y
Rtn1 gnf1m15854_at 94545_at 104001 6252 N
Irf6 gnf1m13081_at 92440_at 54139 3664 N
Rcn2 gnf1m24916_at 93281_at 26611 5955 Y
Tes gnf1m02859_at 101551_s_at 21753 26136 Y
Sel1L gnf1m30768_a_at 92870_at, 92871_at 20338 6400 N
Rnf4 gnf1m25286_at 93782_at 19822 6047 Y
Galnt3 gnf1m24047_at 99011_at 14425 2591 Y
Cradd gnf1m27661_at 102952_g_at 12905 8738 Y
Clca1 gnf1m13262_a_at 103812_at 12722 1179 YBMC Bioinformatics 2005, 6:S7
Page 8 of 9
(page number not for citation purposes)
homologene database http://www.ncbi.nlm.nih.gov/ent
rez/query.fcgi?db=homologene and the corresponding
orthologous human Entrez Gene identifier (HsEG) was
selected. A Perl http://www.perl.org script was used to link
HsEG to all the accession numbers of EST associated with
them in the UniGene database (downloaded from http://
ftp.ncbi.nih.gov on 3/3/2005). The ESTs accession num-
bers were then searched in the van't Veer data set [26],
together with the Her2 gene. In this experiment, RNA
expression for each of the 78 breast cancer tumors is eval-
uated as the log10 differential expression with respect to a
pool composed by mixing the same amount of all RNA of
the sporadic patients [26].
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